June Off to a Poor ...
Health Care: Drugs
Allos Therapeutics Inc. (ALTH: NASDAQ)
$1.77 -0.01 | -0.56%
06/01/12 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 1.77 |
| 52 Week High | 2.30 |
| 52 Week Low | 1.25 |
| Avg. Daily Vol. (Mil) | 2.34 |
| Beta (3 year) | 0.48 |
| Share Related Items | |
| Mkt Cap (Mil) | 189.32 |
| Shares Out (Mil) | 106.96 |
| Float (Mil) | 77.08 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 5.20 |
| Current Ratio | 5.30 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 2.47 |
| Price/Book | 2.67 |
| Price/Cash Flow | -7.50 |
| Per Share Data | |
| Earnings | -0.26 |
| Sales | 0.72 |
| Book Value | 0.66 |
| Cash Flow | -0.24 |
| Business Summary | |
|---|---|
| Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer. | |
| General Information | |
| 11080 Circlepoint Road
Suite 200 Westminster, CO 80020 |
|
| www.allos.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 111 | |
| CEO: Mr. Paul L. Berns | |
| Short Interest | |
| Current Month (Mil) | 3.20 |
| Previous Month (Mil) | 3.84 |
| Short Interest Ratio (Days) | 2.20 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -23.70 |
| Return on Investments | -37.00 |
| Profitability | |
| Gross Margin | 78.80 |
| EBIT Margin | -34.80 |
| Profit Margin | -34.80 |
Portfolios with ALTH
- Portfolio NameUser Type
- UserSaveyn walter
- ContributorStocks Under-$10 Setting Up...
- Userrab 's
- Usergdean1
- User$5 stocks
- UserStocks Under $5
- UserLegal Tender II
- UserTop Picks Under $5 for 2011...
- ContributorTop Stock Picks Under $5 fo...
- UserWatch List - Healthcare / B...
Latest ALTH Headlines from TheStreet
- Monday's Top 10 Articles, Videos on TheStreet 04.09.12 | 03:04 pm
- Spectrum Pharma: The Growth Party is Over 04.09.12 | 06:04 am
- Allos Stock Gaps Down On Today's Open (ALTH) 01.20.12 | 09:01 am
- Biotech Stock Mailbag: Amarin, Spectrum, Arena 01.06.12 | 06:01 am
- Spectrum Pharmaceuticals CEO: "We Are Always Looking for the Diamond in the Rough."
12.01.11 | 06:12 am - Next Step for Amag's Board: Fire CEO, Sell the Company. 10.21.11 | 11:10 am
- Biotech Stock Mailbag: Keryx Pharma 10.14.11 | 06:10 am
- Activist Fund Manager Ups Stake in Amag Pharma to Stop Merger With Allos 10.10.11 | 10:10 am
- Spectrum Pharma Said to Make Bid for Allos 09.21.11 | 11:09 am
- Biotech Stock Mailbag: Vivus 09.16.11 | 05:09 am
Press Releases for ALTH
- Allos Therapeutics (Graphic: Business Wire) - Business Wire 05.24.12 | 07:05 pm
- Spectrum Pharmaceuticals And Allos Therapeutics Announce Extension Of Previously Announced Tender Offer For Shares Of Allos Therapeutics - Business Wire 05.10.12 | 07:05 am
- Spectrum Pharmaceuticals Commences Tender Offer For All Outstanding Shares Of Allos Therapeutics - Business Wire 04.16.12 | 08:04 am
- Allos Therapeutics, Inc. (ALTH) Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Spectrum Pharmaceuticals - PR Newswire 04.05.12 | 10:04 am
- Spectrum Pharmaceuticals To Acquire Allos Therapeutics: Acquisition Expected To Be Accretive On A Cash Basis In Q4 Of 2012 - Business Wire 04.05.12 | 07:04 am
- Allos Therapeutics Reports Fourth Quarter And Full Year 2011 Financial Results - Business Wire 03.06.12 | 04:03 pm
- Allos Therapeutics To Report Fourth Quarter And Full Year 2011 Results On March 6, 2012 - Business Wire 02.21.12 | 08:02 am
- Allos Therapeutics Requests Re-Examination Of CHMP Opinion On FOLOTYN® In PTCL At The European Medicines Agency - Business Wire 01.30.12 | 08:01 am
- Allos Therapeutics Announces Interim Results From Phase 1 Combination Study Of FOLOTYN® And Bexarotene Demonstrate Activity In Patients With Relapsed Or Refractory Cutaneous T-cell Lymphoma - Business Wire 01.30.12 | 08:01 am
- Allos Therapeutics Receives Negative Opinion From The CHMP On FOLOTYN - Business Wire 01.20.12 | 07:01 am
Partner Headlines for ALTH
- Company News for April 9, 2012 - Corporate Summary - Zacks 04.09.12 | 10:04 am
- Time To Take Another Look At The Biotechnology Sector - Seeking Alpha 04.09.12 | 09:04 am
- Benzinga's M&A Chatter for Thursday April 5, 2012 - Benzinga 04.08.12 | 01:04 pm
- Futures Steer Lower; Spectrum Pharmaceuticals Dives - Investor's Business Daily 04.05.12 | 09:04 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 03.30.12 | 09:03 am
- Allos Narrows Loss - Analyst Blog - Zacks 03.07.12 | 09:03 am
- ALTH Seeks Review of Folotyn Verdict - Analyst Blog - Zacks 02.06.12 | 06:02 pm
- Loss Shrinks at AMAG, CEO Departs - Analyst Blog - Zacks 11.08.11 | 10:11 am
- Company News for November 4, 2011 - Corporate Summary - Zacks 11.04.11 | 10:11 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 10.25.11 | 09:10 am
